ArticleAntimicrobial agents and chemotherapy2004
Antimicrobial and antileishmanial activities of hypocrellins A and B.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Surface modification and nanodelivery of hypocrellin-based photosensitizers: photophysical optimization and biomedical applications.Journal of nanobiotechnology · 2026Review
- Fruiting body-associated Pseudomonas contact triggers ROS-mediated perylenequinone biosynthesis in Shiraia mycelium culture.Bioresources and bioprocessing · 2025Article
- Enhancement of Perylenequinonoid Compounds Production from Strain ofMicroorganisms · 2025Article
- Hypocrellin A from an ethnic medicinal fungus protects against NLRP3-driven gout in mice by suppressing inflammasome activation.Acta pharmacologica Sinica · 2025Article
- Production of fungal hypocrellin photosensitizers: Exploiting bambusicolous fungi and elicitation strategies in mycelium cultures.Mycology · 2025Review
- The impact of histone lactylation on the tumor microenvironment and metabolic pathways and its potential in cancer therapy.Genes & genomics · 2024Review
- Rapid Degradation of Rhodamine B through Visible-Photocatalytic Advanced Oxidation Using Self-Degradable Natural Perylene Quinone Derivatives-Hypocrellins.Bioengineering (Basel, Switzerland) · 2022Article
- Temperature-responsive regulation of the fermentation of hypocrellin A by Shiraia bambusicola (GDMCC 60438).Microbial cell factories · 2022Article
- Antimicrobial photodynamic inactivation as an alternative approach to inhibit the growth ofFrontiers in microbiology · 2022Article
- Fungal perylenequinones.Mycological progress · 2022Review
- The promise of low-intensity ultrasound: A review on sonosensitizers and sonocatalysts by ultrasonic activation for bacterial killing.Ultrasonics sonochemistry · 2021Review
- Anti-leishmanial compounds from microbial metabolites: a promising source.Applied microbiology and biotechnology · 2021Review
- Phylogenetic Position ofJournal of fungi (Basel, Switzerland) · 2021Article
- Antimicrobial photodynamic therapy with hypocrellin B against SARS-CoV-2 infection?Photodiagnosis and photodynamic therapy · 2021Article
- FeInternational journal of molecular sciences · 2021Article
- Microorganisms as a Potential Source of Molecules to Control Trypanosomatid Diseases.Molecules (Basel, Switzerland) · 2021Review
- Antifungal activity of hypocrellin compounds and their synergistic effects with antimicrobial agents against Candida albicans.Microbial biotechnology · 2021Article
- Anti-leishmanial and anti-trypanosomal natural products from endophytes.Parasitology research · 2021Review
- Enhanced Production and Anticancer Properties of Photoactivated Perylenequinones.Journal of natural products · 2020Article
- Phytochemical, in-vitro biological and chemo-preventive profiling of Arisaema jacquemontii Blume tuber extracts.BMC complementary and alternative medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hypocrellins A and B were evaluated for in vitro antimicrobial and antileishmanial activities. Hypocrellin A exhibited promising activity against Candida albicans and moderate activity against Staphylococcus aureus, methicillin-resistant S. aureus, Pseudomonas aeruginosa, and Mycobacterium intracellulare. Hypocrellin B showed weak antimicrobial activities. Hypocrellin A exhibited potent antileishmanial activity, while hypocrellin B was only moderately active. These results of promising antifungal and antileishmanial activity of hypocrellin A may be useful for further structure-activity relationship and in vivo studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.